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Abstract
Comorbidity in patients, along with attendant operations and complications, is asso-
ciated with reduced long-term survival probability and an increased need for health-
care facilities. This study proposes a user-friendly toolkit to design an adjusted
case-mix model of the risk of comorbidity for use by the public for its incremental
development. The proposed model, Temporal Comorbidity-Adjusted Risk of Emer-
gency Readmission (T-CARER), introduces a generic method for generating a pool
of features from re-categorised and temporal features to create a customised comor-
bidity risk index.
Research on emergency admission has shown that demographics, temporal dimen-
sions, length of stay, and time between admissions can noticeably improve statistical
measures related to comorbidities. The model proposed in this study, T-CARER,
incorporates temporal aspects, medical procedures, demographics, admission details,
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and diagnoses. And, it tries to address four weakness areas in popular comorbidity
risk indices: robustness, temporal adjustment, population stratification, and inclu-
sion of major associated factors.
Three approaches to modelling, a logistic regression, a random forest, and a wide
and deep neural network, are designed to predict the comorbidity risk index as-
sociated with 30- and 365-day emergency readmissions. The models were trained
and tested using England’s Hospital Episode Statistics inpatient database for two
time-frames: 1999–2004 and 2004–2009, and various risk cut-offs. Also, models are
compared against implementations of Charlson and Elixhauser’s comorbidity indices
from multiple aspects. Tests using k − fold cross-validation yielded stable and con-
sistent results, with negative mean-squared error variance of -0.7 to -2.9. In terms
of c-statistics, the wide and deep neural network and the random forest models out-
performed Charlson’s and Elixhauser’s comorbidity indices. For the 30- and 365-day
emergency readmission models, the c-statistics ranged from 0.772 to 0.804 across the
timeframes.
The wide and deep neural network model generated predictions with high precision,
and the random forest model performed better than the regression model, in terms
of the micro-average of the F1-score. Our best models yielded precision values in the
range of 0.582–0.639, and an average F1-score of 0.730–0.790.
The proposed temporal case-mix risk model T-CARER outperforms prevalent mod-
els, including Charlson’s and Elixhauser’s comorbidity indices, with superior preci-
sion, F1-score, and c-statistics. The proposed risk index can help monitor the tem-
poral comorbidities of patients and reduce the cost of emergency admissions.
Keywords: Comorbidity Risk Index, Temporal Model, Hospital Episode Statistics,
Emergency Admission, Deep Neural Network
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1. Introduction
There is increasing evidence that the quantification of high-risk diagnoses, operations
and procedures, and monitoring changes over time can significantly improve the
quality of readmission models with adequate adjustment.
Many countries are developing strategies to reduce avoidable hospital care [1, 2].
Over the last decade, the National Health Service (NHS) of England has been trans-
formed through efficiency-inducing measures, such as payment reform, and quality
improvement measures, such as marginal rate tariffs [3]. Another approach, that
has been adopted, is the use of ambulatory care sensitive conditions (ACSC)1 as a
general indicator for the optimality assessment of primary care, community services,
and outpatient care [4, 5, 6, 7]. At present, 27 ACSC have been specified in the NHS
Outcomes’ Framework [8, 9] as markers of improved health outcomes.
Two streams of work have generally been pursued on risk-scoring comorbidities to
predict resource utilisation, emergency admission, and mortality. One stream of re-
search in the area examines the odds ratio of major diagnoses groups and is thus
highly reliant on statistics concerning the entire given population. These models
crudely sum up the derived weights for comorbidities based on the most recent ad-
mission data of patients without regard for temporal patterns. A popular example is
the Charlson Comorbidity Index (CCI) [10], which relies on 22 comorbidity groups.
A recent implementation of the CCI is the NHS England’s version of the CCI (NHS-
1The ambulatory care sensitive conditions are also known as the primary care sensitive condi-
tions.
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CCI) that is continually being updated [11, 12, 13, 14, 15].
The second stream of models uses a diagnosis classification approach based on the
similarities, type, likelihood, and duration of care. However, these measures are
usually complex and are specialised to particular settings and populations. These
models have also used a period of care records in the past, but have ignored temporal
patterns.
One prominent method in this vein is the Elixhauser Comorbidity Index (ECI) [16,
17], which relies on 30 comorbidity groups and a one-year lookback period. Unlike
the CCI, the ECI uses diagnosis-related groups (DRG) that were first developed by
Fetter et al. [18, 19]. The DRG is based on data concerning diagnoses, procedures,
age, sex, discharge status, complications, and comorbidities collected by the ICD
(International Statistical Classification of Diseases and Related Health Problems).
A recent adaptation of the ECI is the Agency for Healthcare Research and Quality
(AHRQ) version of ECI, which is actively maintained by the US Public Health Service
[17]. In England, the ECI has not been adapted, but the defined diagnoses groups
are adopted in variety of researches that use England administrative data [20].
Another well-known method is John Hopkins’ [21] adjusted clinical groups (ACGs),
which is a commercial tool. The model uses a minimum of six-month and a max-
imum of one-year prior care records to encapsulate 32 diagnoses groups, known as
aggregated diagnosis groups (ADGs), where their aggregations are called expanded
diagnosis clusters (EDCs).
An alternative approach to comorbidity scoring is to use a cost function, like the
UK’s Healthcare Resource Groups (HRG) [22], the US’s Centers for Medicare and
Medicaid Services Hierarchical Condition Categories (CMS-HCC) [23, 24], or Verisk
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Health’s diagnostic cost group (DxCG) Medicare models [25]. It has been demon-
strated [26, 27] that use of cost functions, like HRG, can improve comorbidity models
performance.
In summary, these indices are initially developed to adjust for particular risks, such
as the risk of mortality and care utilisation, but are commonly used in a variety of
risk adjustment problems in critical care research.
In the machine learning pipeline developed in our previous study [28], the comorbidity
index is a significant factor with high potential for further improvement. Moreover,
little research has been conducted on temporal comorbidity risk scores [29], and the
majority of temporal models [30] in the literature have focused on survival analysis in
comorbidity indices. Moreover, the majority of popular comorbidity scores are either
based on very old research [31, 32, 33, 34], or their performance indicators have been
controversial [35]. For example, Moore et al. [36] compared the CCI across several
models and concluded that it has high prediction power, but is highly dependent
on the accuracy of records, comorbidity group, population, and healthcare settings.
Furthermore, the majority of comorbidity risk models consider only the most recent
admission and the first few diagnoses of a given patient to rank his or her risk of
comorbidity. However, very sick and comorbid patients usually have multiple medical
conditions and operations, or procedures involving complex conditions.
However, comorbidity risk models are constrained by population and sample char-
acteristics, data quality (e.g. missing diagnoses, or delayed death registration), and
modelling approach. Therefore, a wide range of literature [37, 33, 38, 39, 40, 41, 42]
has focused on modifying and benchmarking comorbidity indices, using different
datasets, cohorts, complexity, length of stay, and claims. Also, many attempts have
been made to score the surgical outcomes and complications stemming from co-
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morbidity [39, 43]. However, they are mainly based on non-administrative clinical
variables, or are specialised to specific outcomes and populations.
There are four major areas that comorbidity index models can improve. First, to
make the risk score relevant to different environments, an approach is needed to
model complex correlations between variables and states. Second, to better distin-
guish between short- and long-term conditions, temporal dimensions may be included
in the form of a life table [44] or a polynomial weight function [45]. Third, population
stratification is a major factor in the prevalence of medical conditions that must be
adjusted. Fourth, major factors correlated to diagnoses must be included directly
(observable) or indirectly (latent) to improve the risk estimates, including secondary
diagnoses, operations, procedures, and complications [46, 47].
The main outcome of this research is to develop a comorbidity model that can be
adjusted by demographics, as well as the temporal patterns of comorbidity and major
associated factors. And, the aim is to include only a set of generic features not specific
to England’s healthcare population and settings.
The second outcome of this research is a generic, open-source, and easy-to-use en-
vironment to model the risk of comorbidity. The proposed Temporal Comorbidity-
Adjusted Risk of Emergency Readmission (T-CARER) model allows us to address
the four above-mentioned issues. The toolkit consists of a user-friendly IPython
Notebook that calls procedures in MySQL, Python, and third-party libraries 2. The
T-CARER toolkit and documentations are available online under Apache License
(Version 2.0) [48]: https://github.com/mesgarpour/T-CARER.
2The main libraries are: Python (3.4), TensorFlow with GPU support (1.0), Cuda (8.0), SciKit-
Learn (0.18), Numpy (1.7.1), and SciPy (0.18).
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T-CARER was developed using two five-year samples across a 10-year period from
England’s Hospital Episode Statistics’ (HES) inpatient database. In England, admin-
istrative data collected by the NHS for secondary care are recorded to the Secondary
Uses Service (SUS) database by hospitals. This database contains details of admis-
sions, clinical demographics, and finances for all three sectors: inpatient, outpatient,
and accident and emergency (A&E). The NHS also publishes a cleaned, less clinical,
and thoroughly validated version of the SUS on a monthly basis, known as the HES
database.
Several stages of analyses were carried out to test and benchmark T-CARER. First,
two data-frames across a 10-year period were selected. Then, three modelling ap-
proaches were developed: a logistic regression, a random forest, and a wide and deep
neural network (WDNN). These models were benchmarked against our implemen-




In this study, a bespoke extract of the HES inpatient data was used that contained
records from April 1999 to March 2009. Two samples were randomly selected from
this database, including 20% of total unique patients from 1999–2004 and 2004–2009.
Each main sample was then divided into two equal halves to be used for training and
testing. The specifications of the selected data sets are presented in Table 1.
Each time frame was divided into one year of trigger-event, a year of prediction-period,
and three years of prior-history. The population included all living patients older
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Table 1
Selected samples from the HES inpatient database.
Samples Time frame
Population size Sample size Selected population




Sample-1 1999/04 - 2004/03 18,885,777 7,206,133 6,347,067 1,441,227 1,157,873 492,458 148,950
Sample-2 2004/04 - 2009/03 31,731,488 8,104,748 11,394,152 1,615,347 1,410,923 395,522 110,961
than one year that had been admitted within the trigger year. The prediction targets
were 30- and 365-day emergency hospital admission to inpatient ward. The statistical
analysis of the data sets, including population characteristics, was performed in
previous stage of our study [30].
2.2. Features
Following data extraction, several stages of data pre-processing and feature selection
were carried out using the framework introduced by Mesgarpour et al. [50]. Before
carrying out feature selection, the features were aggregated and split into temporal
events, to be captured through time. Definitions of main features are presented in
Table 2.
2.2.1. Pre-processing
The pre-processing steps implement data selection, removal of invalid records, and
the imputations of observations (Fig. A.1). Feature re-categorisation is also applied
in this stage to reduce sparsity and better capture non-linear relationships (Fig.
A.2).
In the re-categorisation step, a clinical grouper known as the Clinical Classifications
Software (CCS) is used to categorise the diagnoses, to better capture the patterns
and cross-correlations of the comorbidities (Table 3). The CCS clusters the the ICD-
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Table 2
Definition of the main features considered initially.
Main feature Definition
gender Gender of patient (Female, Male, Other)
ethnos Ethnicity of patient (Bangladeshi, Black African, Black Caribbean, Black Other, Chinese, Indian,
Pakistani, White, Other).
imd04rk The Index of Multiple Deprivation (IMD): overall ranking of income (22.5%), employment (22.5%),
health deprivation and disability (13.5%), education & skills (13.5%), barriers to housing & services
(9.3%), crime (9.3%), & living environment (9.3%).
ageTrigger Age of patient at the trigger event. Categorisation bins: {10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65,
70, 75, 80, 85, 90+}.
gapDays (temporal) Delta-times from discharge to the trigger admission.
epidur (temporal) Spell durations.
preopdur (temporal) Pre-operative durations.
posopdur (temporal) Post-operative durations.
operOPCSL1 (temporal) The level-1 categories (25 groups) of operating procedure codes (OPCS), the national standard [51]
version 4.0 (∼4,000 codes).
diagCCS (temporal) The level-1 categories (302 groups) of Clinical Classifications Software (CCS) for ICD-10 [17] diagnoses
(∼69,800 codes).
admimeth (temporal) The level-1 categories (3 groups) of admission method (20 codes): {Elective, Emergency, Other}.
mainspef (temporal) The level-1 categories (33 groups) of the main specialities of the consultants (86 codes), based on the
exploratory analysis.
10 (10th revision of the ICD) diagnoses and operations into a number of categories
that are clinically meaningful [52, 53].
Furthermore, operations and procedures are categorised (Table 3) using the major
categories of the OPCS-4 (OPCS Classification of Interventions and Procedures,
Version 4)3, but alternative coding categorisation may be used, like the ICD-10
Procedure Coding System (PCS). The OPCS-4 is an alphanumeric nomenclature
used by the NHS in England. It contains an implicit categorisation for operations
based on clinical categories rather than cost or risk.
2.2.2. Life table and aggregation
Administrative healthcare data are severely imbalanced in terms of the amount of
longitudinal (panel) data per patient and their distributions over the years. Statisti-
cal methods are not equipped to handle these types of imbalances directly. Therefore,
the life table approach from survival analysis is used to keep track of temporal events
3It is based on the earlier Office of Population Censuses and Surveys Classification of Surgical
(OPCS) Operations and Procedures.
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Table 3
Groups of diagnoses, operations, and consultant specialities that are considered initially.
CCS Diagnoses Conditions: Other complications of pregnancy Nervous system
Abdominal pain Other connective tissue disease Other abdominal organs
Administrative or social admission Other female genital disorders Other bones & joints
Alcohol-related disorders Other gastrointestinal disorders Others
Allergic reactions Other injuries & conditions due to external causes Respiratory tract
Asthma Other lower respiratory disease Skin
Cardiac dysrhythmias Other nervous system disorders Soft tissue
Cataract Other suspected screening (excl. mental & infec-
tious)
Upper digestive tract
Chronic obstructive pulmonary & bronchiec-
tasis
Other skin disorders Upper female Genital
tract
Complication of device; implant or graft Other upper respiratory disease Urinary
Congestive heart failure; nonhypertensive Others Speciality of Consul-
tant:
Coronary atherosclerosis & other heart dis-
ease
Phlebitis; thrombophlebitis & thromboembolism A&E
Deficiency & other anemia Residual codes; unclassified Cardiothoracic
Delirium dementia & amnestic & other cog-
nitives
Skin & subcutaneous tissue infections Ear, nose & throat
Diabetes mellitus without complication Spondylosis; disc disorders; other back problems Gastroenterology
Disorders of lipid metabolism Thyroid disorders General
Esophageal disorders Urinary tract infections General surgery
Essential hypertension Operations Categories: Geriatric
External cause codes Arteries & veins Gynaecology
Fetal distress & abnormal forces of labor Bones & joints of skull & spine Haemotology
Fracture of upper limb Diagnostics & tests Maternity
Genitourinary symptoms & ill-defined condi-
tions
Female genital tract Ophthalmology
Normal pregnancy & delivery Heart Others
OB-related trauma to perineum & vulva Lower digestive tract Paediatrics
Osteoarthritis Lower female genital tract Plastic
Other & unspecified benign neoplasm Male genital organs Psychiatry
Other aftercare Mental health Urology
Other birth complications; mother’s puer-
perium
Miscellaneous operations
[44]. Based on previous studies and initial statistical analyses, four levels of temporal
features were generated: 0–30, 30–90, 90–365, and 365–730 days.
These four levels captured part of the temporal aspect of the comorbidities, in ad-
dition to the delta time between admissions (gapDays) and features related to the
length of stay (epidur) including temporal metadata. Furthermore, in the modelling
stage of WDNN, we applied several techniques to capture the complex temporal
patterns of patients’ comorbidities.
The temporal features were summarised at each temporal level based on several
aggregation functions, including prevalence, count, and average. This stage increased
the number of features by more than 50-fold.
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2.2.3. Feature selection
Following feature generation, a feature pool was produced. The feature selection
step was then carried out (Fig. A.2). The features were filtered out based on their
linear cross-correlation, frequency, and sparsity (percentage of distinctness, and the
ratio of the most common value to the second most common).
Following this, the continuous features were transformed using two feature transfor-
mation methods: scale to mean, and Yeo-Johnson [54]. Both methods can be used to
transform the data to improve normality. Although feature transformations do not
guarantee good convergence or stable variance for any dataset, they have been applied
to avoid inputting skewed features into models. A disadvantage of transformations
is that they make model interpretation more challenging, and can negatively impact
the relationship between correlated features in the model. Therefore, the highly
correlated features were removed after transformations.
Features in the training set were then sorted using the average importance score
produced by the Breiman random forest algorithm [55], using six trials and three
decision tree generation settings (Table A.7).
2.3. Modelling approaches
The aim of this study is to model emergency readmissions using a minimal number
of generic features that can be used for short- and long-term predictions with high
correlation. In this study, the four aforementioned weakness areas of comorbidity
risk indices were attempted to be addressed: robustness, temporal adjustment, pop-
ulation stratification, and directly or indirectly including major associated factors.
Also, in this research, no condition was imposed on the admission type at the trigger
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event, and a minimal number of raw features were used. This makes it different from
general readmission models, such as the ERMER [28], that use a wide range of raw
features and may enforce the emergency admission condition for both trigger events
and future events.
Moreover, as Jeff Hawkins [56] puts it, ”finding a good representation of massive
amounts of knowledge about the world is hard enough; it is compounded by the
need to efficiently extract contextually relevant knowledge depending on the situa-
tion.”
Therefore, based on our literature review, three different modelling algorithms were
considered for training T-CARER on a bespoke high performance workstation4: a
logistic regression, a random forest, and a WDNN.
2.3.1. Logistic regression
The first algorithm employed was logistic regression with L1 regularisation (1.0)
using the liblinear optimisation algorithm [57] with a maximum of 100 iterations
and a warm-up period [58].
Logistic regression is a special case of the generalised linear model (GLM) that has
a binary dependent variable with a logit link function, and an error term with the
standard logistic distribution. The addition of L1 regularisation allows logistic re-
gression to select a simpler model when a moderate number of features with high
sparsity are available.
4CPU: Intel i7-7700K 4.2 GHz 64 bit; GPU: NVIDIA Titan X 1.5 GHz, 12 GB RAM; Memory:
Samsung SM951 512 GB, PCI-E v3 on Intel Z270 chipset; RAM: 4 ∗ 16 GB Corsair DDR4 2666












































Fig. 1. Abstract graph of the implemented WDNN model.
2.3.2. Random forest
We used the random forest method using the Breiman algorithm [55, 58] with
gradient-boosted regression trees and the Gini index criterion on 1,000 trees in the
forest. The minimum split size was set to 100 and the minimum leaf size was con-
figured to 50.
The random forest method is an ensemble decision tree introduced by Breiman et al.
[55]. It is based on the Classification And Regression Tree (CART) algorithm [59]
and the bagging ensemble method [60]. To reduce the correlation between classifiers,
the Breiman algorithm implements a technique to decorrelate the base learning trees
using random feature selection. However, the Breiman random forest is sensitive to
highly correlated features and the scale or categories of features [61, 62].
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2.3.3. Deep neural network
We implemented a deep neural network (DNN) based on the wide and deep neural
network (WDNN) algorithm introduced by Cheng et al. [63]. DNNs [64, 65] are a
class of artificial neural networks (ANNs) with multiple hidden layers, and allow for
modelling of more complex non-linear problems. DNNs behave like ANNs but with a
better ability to form complex non-linear models with a more effective representation
of features in each layer. The WDNN is a DNN that combines the benefits of
memorisation and generalisation. The WDNN consists of two parts: the wide model
and the deep model.
The WDNN embodies two successful models, logistic regression and the deep multi-
layer perceptron (MLP), to leverage the strengths of each. For administrative hospi-
tal data, logistic regression can be considered to model the linear relationship, while
the MLP models the nonlinear portion. It has been shown in the literature [66]
that this structure allows to effectively include prior information and easily learn the
effects of individual risk factors.
The wide part of the model consists of a wide linear model for highly sparse features
(random features that are rarely active), and is good at memorising specific cases.
The wide part may also include groups of crossed features. Inside a group of crossed
features, each level of a feature occurs in combination with each level of other features.
The GLM (Eq. 1) and the cross-product transformation (Eq. 2) for the wide part
are defined as follows:





xckii cki ∈ {0, 1} (2)
where y is the prediction, x is a vector of features of d features, w represents the
model parameters, and b is bias. φk(x) is the k-th transformation for features vector
x.
On the contrary, the deep part of the model consists of hidden layers of a feed-
forward neural network with an embedding layer and several hidden layers for any
other variable [67]. The deep part can be particularly useful for the generalisation of
cross-correlations. Each hidden layer performs the following operation (Eq. 3):
a(l+1) = f(W (l)a(l) + b(l)) (3)
where W (l), a(l), and b(l) represent the weights, actuations, and the bias for layer
l, respectively. Finally, the WDNN for the logistic regression problem (Y ) can be
formulated as follows (Eq. 4):
p(Y = 1|x) = σ(wTwide[x, φ(x)] + wTdeepa(lf ) + b) (4)
where σ(.) is the sigmoid function of the wide and deep features with actuations
and transformations, plus bias. φ(x) represents the cross-product transformations of
x feature, with w. weights. In our study, the WDNN model applied the Adadelta
optimiser [68] for the gradients of the deep part and the rectified linear unit (ReLU)
activation function to each layer of the ANN [69]. The ReLU was used in this study
because of its effective approximation technique for the classification problem. The
ReLU is defined in Eq. 5, where f(x) is the rectifier for input signal x:
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f(x) = max(0, x) (5)
Our first objective in network tuning was to minimise the loss function in learning
iterations, avoid weight decay, and ensure convergence. The second objective was to
maximise the numbers of layers and neurons under limited computational resources
to increase stability.
The developed WDNN was tuned after several stages of ad-hoc cross-validation to
reach an optimised setting for the hyperparameters. Moreover, different regularisa-
tion parameters (i.e. neuron drop-out rates for randomly removing elements) were
tested, where this value was ultimately set to zero. Finally, an implicit optimisa-
tion was set to be carried out in the background, using the Adadelta optimiser, to
configure the learning rate dynamically.
Table 4
The outline of constructed nodes in the WDNN model.
Sub-model Feature type Features
Wide Categorical ageTrigger (17 states), epidur (6 states), ethnos (11 states), gapDays (6 states), gender (2
states), & imd04rk (11 states)
Crossed (memorised) gender ≈ ethnos (80 cross states), imd04rk ≈ gender (200 cross states), imd04rk ≈ ethnos
(400 cross states), & imd04rk ≈ ageTrigger (400 cross states).
Deep Embedded ageTrigger (5 states), ethnos (3 states), gender (2 states), imd04rk (5 states), epidur (3
states), & gapDays. (3 states)
Continuous All the selected categories of admimeth, diagCCS, gapDays, mainspef, operOPCSL1, posop-
dur, & preopdur.
Furthermore, because of the large size of the WDNN, the designed tensors [70] were
trained in batches of 2,000 observations per step for 40,000 iterations in total. The
training of each model using our hardware and software setups took approximately
12 hours (with regular snapshots of training).
The outline of the nodes are presented in Table 4, the abstract representation of
the designed model in TensorFlow is presented in Fig. 1, and the selected features
are defined in Table A.7. Also, Fig. A.3, Fig. A.4, and Fig. A.5 visualise the
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constructed network structure in TensorBoard Graph Visualisation, and display how
nodes, edges, and operators are assembled together [70]. The wide part of the model
consists of 22 categorical features (1–17 states), and four memorised crossed features
(80–400 states). The deep part of the model contains 14 embedding features (3–
5 states), 286 continuous features (1 state), and three hidden layers of neurons.
The defined hidden layers, layers one to three, are fully interconnected, and were
configured as having 24,000, 12,000, and 6,000 nodes, respectively.
Table 5
The performance statistics of T-CARER for all models across two samples.
Time horizon 30-day 365-day
Method RFCa LRb WDNNc RFC LR WDNN
Sample Train Test Train Test Train Test Train Test Train Test Train Test
Sample: Sample-1 (1999–2004)
C-statistics 0.827 0.804 0.778 0.772 0.817 0.796 0.789 0.780 0.760 0.759 0.795 0.787
Precision 0.180 0.180 0.530 0.520 0.641 0.617 0.430 0.430 0.690 0.690 0.644 0.631
Sensitivity d 0.760 0.730 0.070 0.070 0.104 0.098 0.710 0.700 0.260 0.270 0.382 0.374
F1 e 0.300 0.280 0.130 0.130 0.178 0.170 0.540 0.530 0.380 0.380 0.480 0.470
Micro F1 0.790 0.790 0.900 0.900 0.900 0.900 0.740 0.730 0.770 0.770 0.790 0.790
Accuracy 0.728 0.724 0.926 0.925 0.928 0.928 0.718 0.713 0.802 0.802 0.808 0.805
Log-loss 9.392 9.538 2.571 2.576 2.476 2.496 9.746 9.914 6.840 6.835 6.636 6.748
Brier-score 0.168 0.171 0.061 0.061 0.059 0.060 0.186 0.188 0.144 0.144 0.137 0.139
TP & FP f 43,494 43,466 43,494 43,466 43,494 43,466 134,101 133,901 134,101 133,901 134,101 133,901
Total 578,936 578,937 578,936 578,937 578,936 578,937 578,936 578,937 578,936 578,937 578,936 578,937
Sample: Sample-2 (2004–2009)
C-statistics 0.766 0.743 0.718 0.715 0.759 0.735 0.791 0.785 0.765 0.766 0.793 0.772
Precision 0.340 0.320 0.580 0.570 0.600 0.582 0.610 0.610 0.690 0.690 0.651 0.639
Sensitivity 0.590 0.550 0.110 0.120 0.207 0.198 0.690 0.690 0.460 0.460 0.585 0.573
F1 0.430 0.400 0.190 0.190 0.308 0.295 0.650 0.650 0.550 0.550 0.616 0.604
Micro F1 0.790 0.780 0.810 0.810 0.830 0.830 0.720 0.720 0.700 0.700 0.720 0.720
Accuracy 0.770 0.756 0.857 0.855 0.862 0.859 0.722 0.717 0.720 0.720 0.728 0.719
Log-loss 7.955 8.416 4.931 5.011 4.738 4.878 9.616 9.775 9.672 9.668 9.397 9.719
Brier-score 0.194 0.197 0.112 0.114 0.107 0.110 0.187 0.190 0.185 0.185 0.176 0.184
TP & FP 47,487 48,207 47,487 48,207 47,487 48,207 120,285 120,838 120,285 120,838 120,285 120,838
Total 322,300 322,301 322,300 322,301 322,300 322,301 322,300 322,301 322,300 322,301 322,300 322,301
a Random forest classification (RFC). b Logistic regression (LR). c Wide and deep neural network (WDNN).
d Recall or true positive rate. e F1-score (F1). f True and false positives.
3. Results
The three T-CARER models (the logistic regression, the random forest, and the
WDNN) were first benchmarked across the two samples and the two prediction tar-
gets: 30- and 365-day emergency readmissions (Table 5). For benchmarking purpose,
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several performance metrics were provided. And, the performance metrics used here
are based on the compared models (CCIs and ECIs) and the commonly accepted
performance measures for classification models.
Overall, the WDNN and the random forest models provided a better fit for 30- and
365-day emergency readmission problems. For the 365-day readmission, the WDNN
produced a marginally better c-statistics (area under the curve) compared with the
random forest, and a significantly better c-statistics than the logistic regression (Fig.
2). Moreover, the WDNN models had high precision (positive predictive value),
accuracy, and micro-average F1-score (i.e. the weighted average of the precision and
sensitivity). On the contrary, the random forest models had high sensitivity (true
positive rate) and F1-score.
Because the classes were highly imbalanced, the precision–recall curve (Fig. 3) was
used to compare the area under the curve, average precision, and average recall.
The plot shows that the areas under the curves were significantly smaller for 30-day
models compared with 365-day models. Further, sample-2 (2004–2009) models had
a larger area under the curve across the models.
Moreover, based on the CCIs and ECIs benchmarks in the literature, T-CARER
performed considerably better for 30-day emergency admissions. However, there
are no previous benchmarking study on the CCIs and ECIs for one-year emergency
admissions target, due to constraints on data collection, poor predictability power,
or different research priorities.
The four selected studies (Table 6) included benchmarks for various versions of CCIs
and ECIs for emergency admission problems. Moore et al. [36] benchmarked the
AHRQ-CCI using the AHRQ State Inpatient Databases from 18 states (2011–2012),
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Fig. 2. Area under the curve (AUC) comparison of random forest (RFC) and WDNN models for
30- and 365-day targets, using the receiver operating characteristic (ROC) curve.
and reported c-statistics of 0.63. Moreover, Mehta et al. [39] reported c-statistics of
0.70–0.76 for CCIs and ECIs using the Texas Medicare data (2006–2011). Further-
more, Bottle et al. [71, 41] benchmarked CCIs using England’s HES data (2007–2009)
and reported c-statistics of 0.57–0.79. Finally, Holman et al. [33] reported c-statistics
of 0.61–0.77 for CCIs, ECIs, and the Multipurpose Australian Comorbidity Scoring
System (MACSS) models based on data from hospitals in Western Australia (1989–
1996). Unfortunately, precision and recall were not reported in these studies, and it
is thus not possible to compare them in a more granular way.
Furthermore, the models of T-CARER were compared against our implementation of
the NHS-CCI across all categories of CCI and the ECI diagnoses (using the 2009–10
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Fig. 3. Precision–recall curve of random forest (RFC) and WDNN models for 30- and 365-day
targets.
diagnoses classification). The profiling tables (Table A.3, Table A.4, Table A.5, and
Table A.6) indicate that T-CARER performed significantly better than the NHS-
CCI for all 46 categories of diagnosis in terms of the true positive rate. WDNN
models (365-day readmission) with risk cut-off of 0.70 outperformed the NHS-CCI
that had risk index greater than or equal four. Moreover, the random forest model,
with risk cut-off of 0.50, recorded a higher accuracy than NHS-CCI, with a score
[10]5 of greater than zero for the majority of diagnoses.
5The CCI score has three risk groups: mild, with CCI scores of 1–2; moderate, with CCI scores
of 3–4; and severe, with CCI scores ≥5.
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Table 6
The selected CCI and ECI benchmark studies for 30-day emergency admission.
Study Data source Time Records Models C-statistics
Moore et al. [36] AHRQ State Inpatient (18 states) 2011–12 Community inpatients AHRQ CCI 0.63
Mehta et al. [39] Texas Medicare data 2006–11 39,616 patients CCIs & ECIs 0.70–0.76
Bottle et al. [71, 41] England’s HES data 2007–09 Inpatients in England CCIs 0.57–0.79
Holman et al. [33] hospitals in Western Australia 1989–96 1,118,989 patients CCIs & ECIs 0.61–0.77
Moreover, the performance of the emergency admission models using only the NHS-
CCI was very poor and thus is not presented here. For instance, the constructed
logistic regression and random forest for the 365-day emergency scenario by using
only the NHS-CCI had c-statistics values of 0.53–0.58 across the samples.
Moreover, the two top T-CARER models (random forest and WDNN) were com-
pared with the NHS-CCI based on eight main comorbidity groups: hypertension,
depression, coronary heart disease, asthma, diabetes, cancer, chronic obstructive pul-
monary disease, and congestive heart failure. The profiling of the comorbidity groups
(Table A.1 and Table A.2) shows that for all the main comorbidity categories, the T-
CARER models outperformed those of the NHS-CCI. This comparisons were based
on 0.70 risk cut-off for T-CARER models (365-day readmission) and NHS-CCI score
of four or more.
Furthermore, the results of training and tests indicate that logistic regression was
more successful in parameter tuning and minimising overfitting, while some minor
overfitting was observed for the WDNN and random forest models.
Finally, a 10-fold cross-validation [72] algorithm was run for the logistic regres-
sion and the random forest, using two test sub-samples: Sample-1 (1999–2004) and
Sample-2 (2004–2009). The cross-validation results were stable and consistent, with
a negative mean squared error (MSE) variance of -0.7 to -2.9 6. The negative MSE
6MSE values close to zero indicate better stability; however, the MSE cannot be compared across
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of an estimator τˆ with respect to an unknown parameter τ is defined as:
MSE(x) = −Eτˆ [(τˆ − τ)2] (6)
The applied k−fold cross-validation algorithm split each sample into 10 equal-sized
random samples. Then, k−1 folds were used for training and one fold for validation.
Thereafter, the k − fold output was generated after the cross-validation had cycled
through all combinations of splits. However, k−fold cross-validation was not carried
out for the WDNN, because DNNs are expensive to train, and the stability of the
model relies on the amount of data, number of epochs, and learning rate.
4. Discussion
We compared the performance of T-CARER models against commonly used comor-
bidity index models using different samples and population cohorts across a 10-year
period. Overall, our comparisons of T-CARER with the NHS-CCI for different cat-
egories of diagnosis show that it delivered the best performance for the majority of
comorbidity groups, and generated better results than previous surveys of CCIs and
ECIs.
Furthermore, the progression of patients’ comorbidities over time and patterns of
care utilisation can have a significant impact on the performance of comorbidity
models, and it is important that modelling algorithms are equipped to capture tem-
poral changes and interactions among correlated factors. T-CARER’s performance,
in terms of predicting 30- and 365-day emergency readmissions, indicate that it can
samples.
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supersede conventional risk scoring methods, owing to greater flexibility in modelling
and customisation. Moreover, boosting algorithms, such as random forest, and deep
learning models, such as WDNN, can adequately learn multiple levels of complexi-
ties.
In the best-case scenario, a comorbidity score can perform only as well as the in-
cluded diagnostic categories and their correlated factors [73]. The deployment of
a healthcare pre-processing framework [50] helped systematically perform the data
pre-processing and feature engineering for comorbidity risk scoring. Furthermore,
the CCS allowed to categorise ICD-10 diagnoses into a manageable number of clin-
ically meaningful categories. And, the CCS clinical grouper made it simpler to un-
derstand patterns of diagnoses and easily add a wider range of comorbidity groups
[74, 52, 53].
Benchmarking comorbidity risk scores can be very useful as it offers more insight into
the strengths and weaknesses of models. Our benchmarking shows that the random
forest modelling method can lead to a low level of positive predictive value but high
sensitivity. In contrast, the proposed deep learning model (WDNN) can produce
models with high precision, but with weak sensitivity.
Overall, the micro-average of F1-scores for the WDNN model was greater across
samples and prediction targets, but came at a high training cost. In contrast, the
implemented logistic regression models could train only estimators with weak overall
performance and high bias.
However, logistic regression allows for the best interpretation of the resulting model.
Although the global interpretability of random forest and WDNN is difficult, it is
possible to understand the local level and manually validate local predictions (i.e.
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local interpretability) [75].
In summary, the proposed temporal case-mix risk models outperformed prevalent
models with superior precision, F1-score, and c-statistics. The developed risk in-
dex can help monitor temporal comorbidities of patients, and can reduce the cost
of inappropriate hospital and A&E admissions. The T-CARER model can bring
about a significant improvement in scoring comorbidity and assessing the health of
patients.
5. Conclusions
This study proposed an approach to score commodities by the inclusion of diverse
categories of diagnoses, operations, and complexities. The proposed T-CARER mod-
els perform consistently across tests and validations, and outperform Charlson and
Elixhauser indices, which are widely used to predict the risk of comorbidity.
Moreover, the temporal model of comorbidities, operations and complexities was
proved to notably improve the comorbidity risk model. Also, inputting a pool of
features into the feature selection was lead to the discovery of important factors,
including comorbidity groups, operations and complexities.
Overall, the WDNN model can better generalise unseen features using dense embed-
ding in the deep part of the ANN. It can also memorise feature interactions using
the cross-product of features in the wide part of the ANN.
Moreover, the T-CARER toolkit has been produced for use by public as a generic,
user-friendly, and open-source toolkit.
Finally, to adapt the risk stratification models to different healthcare settings, fu-
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ture studies on the development of admission models using transfer learning [76]
approaches are desirable. Moreover, the deployment of process-mining techniques
[77], which could not be derived in this research, could help with identifying more
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however, available from the authors upon reasonable request, and with the permission
of NHS Digital.
25
Details of the variables and definitions of the derived models are available from the
authors at the HSCMG (HSCMG@westminster.ac.uk).
The T-CARER software package was constructed using open-source standards, and
is available online (https://github.com/mesgarpour/T-CARER).
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Set the England Hospital Episode Statistics (HES) Database Connection:
Connect to the HES Inpatient table.
Select a Sample of Patients:
Find patients admitted within the trigger-year, and select randomly 20% of the patients.
Export the Selected Patients Records:a
SET episodes TO
Select episodes with admission date within the selected timeframe for the selected patients.
ORDER episodes BY hesid, admidate, epistart, epiorder, epiend, epikey
a
The required columns are: patient identification (hesid), admission date (admidate), episode start
date (epistart), episode order (epiorder), episode end date (epiend) and episode key (epikey).
Exclude Invalid Records:a
Removing patients with invalid patient identification (hesid), admission date (admidate)b, less than one
year old, died at the trigger event or had no emergency admission during the trigger period.
a
Episodes prior to transfer were not removed.
b
Earliest valid date (1885-01-01); Invalid date (1582-10-15); Missing date (1600-01-01).
Impute Records:
Impute invalid discharge date (disdate), episode end date (epiend)a, discharge method (dismeth), gender
(sex) and ethnicity (ethnos):
disdatespell = MAXspell(disdate)
IF (epiend == NULL AND disdate 6= NULL), THEN epiendspell = MAXspell(disdate) ENDIF
IF (disdate == NULL AND epiend 6= NULL), THEN disdatespell = MAXspell(epiend) ENDIF
IF (MAXspell(disdate) < MAXspell(admidate)), THEN disdatespell = admidate ENDIF
epiend = disdate− admidate




By default discharge date must be NULL, except for transfers and the final episode.
Re-categorisation of features
Fig. A.1. Abstract diagram of the data pre-processing step.
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Filtering Stationary Features:
Removing highly sparse features (constant count: ≥ 95%).
Filtering Correlated Features:
Removing highly linearly correlated features (correlation coefficient: ≥ 80%);
Removing features that their definitions highly overlap.
Exploratory Analysis:
Inspecting distribution and frequency of features.
Transforming Features:




1. Random Forest importance score:
1.1. Trees: number of features, and maximum of 100,000 trees;
1.2. Number of variables selected at each node: 10;
1.3. Sample size: 100, 000 to 700, 000 patients;
2. Support Vector Machine Recursive Feature Extraction (SVM-RFE) importance rank (optional):
1.1. Kernel used in training and predicting: Linear kernel;
1.2. Regularisation term in the Lagrange formulation: 10;
1.3. Re-scaling: scale to zero mean and unit variance;
1.4. Sample size: 10, 000 to 20, 000 patients.
Optional: Step-Wise Feature Selection
Fig. A.2. Abstract diagram of the feature selection step.
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Table A.1
The profile of T-CARER random forest model (365-day readmission) and NHS-CCI, using main comorbidity categories (all
samples).
Main comorbidity groups Population profile T-CARER profile NHS-CCI profile Comparisons





































Sample: Sample-1, Test sub-sample (1999-2004)
Hypertension (HT) 29,207 12,311 22 9 89004 0.296 0.6 27,954 11,017 7,833 51,964 7,079 2,380 23,022 8,962 -8,962 (-10.1%) 10,926 (12.3%)
Depression 21,635 9,925 16 8 69154 0.311 0.611 22,864 7,143 5,849 41,670 6,356 2,130 18,168 7,166 -7,166 (-10.4%) 9,379 (13.6%)
CHDk 20,849 11,669 16 8 57550 0.222 0.504 13,540 7,616 6,146 30,555 3,871 1,547 19,360 7,776 -7,776 (-13.5%) 7,762 (13.5%)
Cancer 20,475 9,888 24 7 80579 0.479 0.768 42,240 4,699 3,921 56,183 2,054 708 14,643 5,589 -5,589 (-6.9%) 6,479 (8.0%)
Asthma 10,196 3,576 43 6 32718 0.356 0.67 12,405 4,272 2,489 20,033 559 267 18,073 5,124 -5,124 (-15.7%) 10,752 (32.9%)
Diabetes 11,249 5,799 20 8 31673 0.259 0.56 8,730 4,067 2,941 17,483 14,307 4,545 8,014 3,400 -3,400 (-10.7%) 11,435 (36.1%)
COPDl 9,144 4,729 14 9 19892 0.119 0.351 2,482 4,621 3,017 7,731 542 303 10,935 4,839 -4,839 (-24.3%) 3,318 (16.7%)
CHFm 9,248 4,466 15 10 20838 0.097 0.29 2,098 4,468 3,457 8,133 1,083 559 11,385 4,937 -4,937 (-23.7%) 3,515 (16.9%)
Prior 30-day non-emergency 781 310 43 9 2203 0.291 0.61 676 374 238 1,184 71 35 272 112 -112 (-5.1%) -42 (-1.9%)
Prior 30-day emergency 112,57039,530 46 6 360657 0.331 0.64 126,30844,469 23,167 224,920 11,348 4,223 48,512 18,579 -18,579 (-5.2%) 13,891 (3.9%)
Sample: Sample-2, Test sub-sample (2004-2009)
Hypertension (HT) 40,163 16,555 23 7 85422 0.232 0.574 21,913 11,178 3,845 41,414 7,908 3,425 30,744 16,271 -16,271 (-19.0%) 15,111 (17.7%)
Depression 32,312 14,583 17 8 69956 0.224 0.554 17,409 7,711 3,270 34,374 7,481 3,230 27,170 14,424 -14,424 (-20.6%) 13,727 (19.6%)
CHD 21,714 11,662 18 7 42427 0.171 0.481 8,037 5,819 2,322 18,391 3,372 1,725 20,758 11,267 -11,267 (-26.6%) 8,816 (20.8%)
Cancer 15,732 6,965 25 7 33143 0.227 0.567 8,408 4,198 1,601 15,810 1,602 757 12,386 6,783 -6,783 (-20.5%) 4,847 (14.6%)
Asthma 14,124 4,562 46 6 31962 0.312 0.682 11,086 4,956 1,400 16,438 805 424 18,387 7,715 -7,715 (-24.1%) 9,653 (30.2%)
Diabetes 13,006 6,482 21 8 27138 0.221 0.56 6,649 3,489 1,357 12,775 11,730 4,834 10,368 5,794 -5,794 (-21.3%) 10,113 (37.3%)
COPD 10,717 5,439 16 7 18912 0.123 0.41 2,507 4,126 1,481 6,714 722 436 12,365 7,007 -7,007 (-37.0%) 4,163 (22.0%)
CHF 9,686 4,700 14 9 16361 0.095 0.348 1,670 3,371 1,343 5,332 1,004 598 10,722 6,470 -6,470 (-39.5%) 3,315 (20.3%)
Prior 30-day non-emergency 755 283 41 6 1394 0.201 0.567 309 311 76 563 59 35 343 200 -200 (-14.3%) 91 (6.5%)
Prior 30-day emergency 120,83839,590 48 5 322301 0.411 0.764 147,81539,168 9,021 192,442 12,321 5,052 55,456 26,535 -26,535 (-8.2%) 27,169 (8.4%)
a The Charlson Comorbidity Index (CCI) diagnoses groups. b Total number of patients with prior spells. c The Inter-Quartile Range (IQR) of patients’ age.
d The IQR of patients’ length-of-stay. e Sensitivity, 50% cut-off point. f F1 score, 50% cut-off point. g True Positive (TP), 50% cut-off point. h True Negative (TN),
50% cut-off point. i Total number of patients scored between 1 to 3 by the NHS-CCI. j Subtraction of TCARER’s True Positive (50% cut-off point) from the NHS-CCI of 4+.
k Coronary heart disease (CHD). l Chronic obstructive pulmonary disease (COPD). m Congestive heart failure (CHF).
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Table A.2
The profile of T-CARER WDNN model (365-day readmission) and NHS-CCI, using main comorbidity categories (all samples).
Main comorbidity groups Population profile T-CARER profile NHS-CCI profile Comparisons





































Sample: Sample-1, Test sub-sample (1999-2004)
Hypertension (HT) 29,207 12,311 22 9 89004 0.109 0.47 11,613 51,212 4,630 58,409 7,079 2,380 23,022 8,962 -8,962 (-10.1%) 17,371 (19.5%)
Depression 21,635 9,925 16 8 69154 0.089 0.419 7,426 41,098 2,004 46,547 6,356 2,130 18,168 7,166 -7,166 (-10.4%) 14,256 (20.6%)
CHDk 20,849 11,669 16 8 57550 0.117 0.455 8,238 29,601 2,454 35,477 3,871 1,547 19,360 7,776 -7,776 (-13.5%) 12,684 (22.0%)
Cancer 20,475 9,888 24 7 80579 0.051 0.332 4,949 55,706 1,564 59,401 2,054 708 14,643 5,589 -5,589 (-6.9%) 9,697 (12.0%)
Asthma 10,196 3,576 43 6 32718 0.116 0.51 4,447 19,742 2,112 21,886 559 267 18,073 5,124 -5,124 (-15.7%) 12,605 (38.5%)
Diabetes 11,249 5,799 20 8 31673 0.12 0.468 4,585 16,663 1,433 19,766 14,307 4,545 8,014 3,400 -3,400 (-10.7%) 13,718 (43.3%)
COPDl 9,144 4,729 14 9 19892 0.218 0.577 5,197 7,071 1,912 9,895 542 303 10,935 4,839 -4,839 (-24.3%) 5,482 (27.6%)
CHFm 9,248 4,466 15 10 20838 0.183 0.531 4,656 7,961 1,474 10,849 1,083 559 11,385 4,937 -4,937 (-23.7%) 6,231 (29.9%)
Prior 30-day non-emergency 781 310 43 9 2203 0.146 0.532 380 1,154 183 1,357 71 35 272 112 -112 (-5.1%) 131 (5.9%)
Prior 30-day emergency 112,57039,530 46 6 360657 0.117 0.519 49,548 219,15729,322 241,351 11,348 4,223 48,512 18,579 -18,579 (-5.2%) 30,322 (8.4%)
Sample: Sample-2, Test sub-sample (2004-2009)
Hypertension (HT) 40,163 16,555 23 7 85422 0.235 0.598 23,876 29,461 9,893 41,592 7,908 3,425 30,744 16,271 -16,271 (-19.0%) 15,289 (17.9%)
Depression 32,312 14,583 17 8 69956 0.22 0.575 18,473 24,165 6,952 34,521 7,481 3,230 27,170 14,424 -14,424 (-20.6%) 13,874 (19.8%)
CHD 21,714 11,662 18 7 42427 0.257 0.601 13,125 11,881 5,359 18,430 3,372 1,725 20,758 11,267 -11,267 (-26.6%) 8,855 (20.9%)
Cancer 15,732 6,965 25 7 33143 0.236 0.592 9,345 10,891 3,648 15,894 1,602 757 12,386 6,783 -6,783 (-20.5%) 4,931 (14.9%)
Asthma 14,124 4,562 46 6 31962 0.245 0.634 9,062 12,444 4,266 16,608 805 424 18,387 7,715 -7,715 (-24.1%) 9,823 (30.7%)
Diabetes 13,006 6,482 21 8 27138 0.24 0.598 7,772 8,931 3,181 12,846 11,730 4,834 10,368 5,794 -5,794 (-21.3%) 10,184 (37.5%)
COPD 10,717 5,439 16 7 18912 0.338 0.67 7,481 4,077 3,520 6,927 722 436 12,365 7,007 -7,007 (-37.0%) 4,376 (23.1%)
CHF 9,686 4,700 14 9 16361 0.345 0.672 6,675 3,165 3,107 5,428 1,004 598 10,722 6,470 -6,470 (-39.5%) 3,411 (20.8%)
Prior 30-day non-emergency 755 283 41 6 1394 0.336 0.688 540 365 273 564 59 35 343 200 -200 (-14.3%) 92 (6.6%)
Prior 30-day emergency 120,83839,590 48 5 322301 0.185 0.604 69,254 162,35634,938 193,319 12,321 5,052 55,456 26,535 -26,535 (-8.2%) 28,046 (8.7%)
a The Charlson Comorbidity Index (CCI) diagnoses groups. b Total number of patients with prior spells. c The Inter-Quartile Range (IQR) of patients’ age.
d The IQR of patients’ length-of-stay. e Sensitivity, 50% cut-off point. f F1 score, 50% cut-off point. g True Positive (TP), 50% cut-off point. h True Negative (TN),
50% cut-off point. i Total number of patients scored between 1 to 3 by the NHS-CCI. j Subtraction of TCARER’s True Positive (50% cut-off point) from the NHS-CCI of 4+.
k Coronary heart disease (CHD). l Chronic obstructive pulmonary disease (COPD). m Congestive heart failure (CHF).
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Table A.3
The profile of T-CARER random forest model and NHS-CCI (365-day), using ECI diagnoses categories (Sample-2, 2004–2009).
Elixhauser comorbidity in-
dex
Population profile T-CARER profile NHS-CCI profile Comparisons





































Congestive heart failure 4,922 2,385 14 10 8,716 0.913 0.724 4,242 962 1,364 3,185 304 163 7,031 4,053 189 (2.2%) 2,510 (28.8%)
AIDS/HIV 102 67 13 6 442 0.676 0.543 69 257 20 329 219 49 89 23 46 (10.4%) 225 (50.9%)
Depression 3,029 1,114 38 8 7,196 0.647 0.585 1,961 2,454 608 3,917 327 142 1,462 733 1,228 (17.1%) 664 (9.2%)
Cardiac arrhythmias 11,194 5,377 14 8 23,006 0.812 0.66 9,089 4,546 2,565 10,603 1,550 764 10,033 5,520 3,569 (15.5%) 4,090 (17.8%)
Valvular disease 2,019 942 16 10 3,957 0.834 0.674 1,683 645 457 1,754 228 109 1,868 1,067 616 (15.6%) 736 (18.6%)
Pulmonary circulation disorder 806 377 22 10 1,745 0.797 0.649 642 408 152 868 101 41 729 397 245 (14.0%) 321 (18.4%)
Peripheral vascular disorders 1,980 1,236 14 11 3,780 0.821 0.674 1,625 583 498 1,612 108 63 3,074 1,650 -25 (-0.7%) 1,281 (33.9%)
Hypertension, uncomplicated 19,370 8,554 18 8 46,496 0.713 0.596 13,813 13,980 3,347 25,568 5,932 2,400 16,643 8,131 5,682 (12.2%) 10,486 (22.6%)
Hypertension, complicated 1,702 911 15 11 3,002 0.845 0.708 1,439 374 466 1,114 52 30 2,701 1,545 -106 (-3.5%) 992 (33.0%)
Paralysis 1,124 570 21 14 2,272 0.818 0.653 919 376 312 1,013 420 194 1,392 740 179 (7.9%) 743 (32.7%)
Other neurological disorders 5,672 2,863 35 8 11,863 0.751 0.662 4,262 3,244 1,438 5,695 604 310 3,513 1,944 2,318 (19.5%) 1,367 (11.5%)
Chronic pulmonary disease 13,510 5,865 30 6 30,516 0.754 0.656 10,184 9,672 4,018 15,589 491 269 24,090 10,669 -485 (-1.6%) 12,226 (40.1%)
Diabetes, uncomplicated 10,110 5,054 21 8 21,907 0.76 0.645 7,687 5,767 2,428 10,779 11,516 4,729 8,737 4,757 2,930 (13.4%) 9,749 (44.5%)
Diabetes, complicated 887 516 21 11 1,603 0.821 0.696 728 240 276 622 248 129 761 472 256 (16.0%) 314 (19.6%)
Hypothyroidism 3,394 685 19 9 7,859 0.767 0.632 2,602 2,233 760 4,142 695 312 2,940 1,539 1,063 (13.5%) 1,461 (18.6%)
Renal failure 3,956 2,173 16 10 6,883 0.858 0.715 3,393 780 1,222 2,492 106 61 6,161 3,556 -163 (-2.4%) 2,215 (32.2%)
Liver disease 1,527 939 22 7 2,955 0.788 0.689 1,204 663 432 1,280 189 96 1,157 668 536 (18.1%) 434 (14.7%)
Peptic ulcer disease 464 233 23 11 1,158 0.81 0.619 376 319 93 662 43 16 711 306 70 (6.0%) 400 (34.5%)
Psychoses 1,121 641 29 31 2,571 0.647 0.573 725 766 206 1,344 103 45 332 175 550 (21.4%) 109 (4.2%)
Lymphoma 462 246 18 10 743 0.764 0.709 353 100 103 222 15 9 478 289 64 (8.6%) 136 (18.3%)
Metastatic cancer 1,650 835 17 8 3,034 0.755 0.642 1,246 398 288 1,185 26 17 2,687 1,461 -215 (-7.1%) 1,036 (34.1%)
Solid tumour 3,510 2,062 18 9 6,425 0.763 0.663 2,677 1,029 684 2,542 131 74 4,750 2,621 56 (0.9%) 1,813 (28.2%)
Rheumatoid arthritis 1,603 458 19 8 3,833 0.783 0.626 1,255 1,076 342 2,045 64 28 3,176 1,369 -114 (-3.0%) 1,658 (43.3%)
Coagulopathy 416 175 40 8 1,003 0.75 0.661 312 371 120 553 42 19 265 140 172 (17.1%) 114 (11.4%)
Obesity 853 343 29 7 2,009 0.734 0.625 626 631 228 1,095 307 136 704 357 269 (13.4%) 457 (22.7%)
Weight loss 709 369 23 12 1,483 0.753 0.633 534 329 106 725 70 29 490 267 267 (18.0%) 215 (14.5%)
Fluid & electrolyte disorders 2,850 1,161 19 14 5,901 0.838 0.654 2,387 992 625 2,771 375 182 2,599 1,372 1,015 (17.2%) 1,140 (19.3%)
Blood loss anemia 69 30 28 8 204 0.638 0.494 44 70 12 127 8 2 51 26 18 (8.8%) 23 (11.3%)
Deficiency anemia 5,006 2,975 33 7 12,003 0.713 0.638 3,571 4,385 1,237 6,589 525 254 2,548 1,361 2,210 (18.4%) 1,050 (8.7%)
Alcohol abuse 2,132 1,313 23 5 5,421 0.646 0.609 1,377 2,275 461 3,148 175 81 997 547 830 (15.3%) 403 (7.4%)
Drug abuse 941 614 13 5 2,548 0.576 0.561 542 1,158 169 1,541 33 15 261 109 433 (17.0%) 104 (4.1%)




Population profile T-CARER profile NHS-CCI profile Comparisons





































a The Elixhauser Comorbidity Index (ECI) diagnoses groups. b Total number of patients with prior spells. c The Inter-Quartile Range (IQR) of patients’ age.
d The IQR of patients’ length-of-stay. e Sensitivity, 50% cut-off point. f F1-score, 50% cut-off point. g True Positive (TP), 50% cut-off point. h True Negative (TN), 50%
cut-off point. i Total number of patients scored between 1 to 3 by the NHS-CCI. j Subtraction of TCARER’s True Positive (50% cut-off point) from the NHS-CCI of 4+.
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Table A.4
The profile of T-CARER random forest model and NHS-CCI (365-day), using CCI diagnoses categories (Sample-2, 2004–2009)
Charlson comorbidity in-
dex
Population profile T-CARER profile NHS-CCI profile Comparisons





































Myocardial infarction 4,079 2,600 21 5 7,806 0.692 0.63 2,821 1,667 602 3,509 396 221 4,493 2,373 448 (5.7%) 2,077 (26.6%)
Peripheral vascular disease 1,980 1,236 14 11 3,780 0.705 0.631 1,625 583 498 1,612 108 63 3,074 1,650 -25 (-0.7%) 1,281 (33.9%)
Cerebrovascular disease 4,651 2,206 16 14 9,911 0.911 0.671 3,640 2,044 830 4,855 598 277 5,457 2,795 845 (8.5%) 2,578 (26.0%)
Dementia 4,020 1,407 9 15 7,766 0.779 0.633 3,556 638 831 3,244 100 55 6,380 3,312 244 (3.1%) 2,611 (33.6%)
Chronic pulmonary disease 13,510 5,865 30 6 30,516 0.956 0.723 10,184 9,672 4,018 15,589 491 269 24,090 10,669 -485 (-1.6%) 12,226 (40.1%)
Rheumatic disease 1,462 394 16 9 3,438 0.261 0.349 1,174 931 318 1,801 34 15 3,110 1,342 -168 (-4.9%) 1,612 (46.9%)
Peptic ulcer disease 695 370 23 10 1,817 0.653 0.558 542 552 120 1,080 76 24 935 405 137 (7.5%) 540 (29.7%)
Mild liver disease 1,393 853 22 7 2,691 0.879 0.722 1,108 596 408 1,162 167 83 1,054 613 495 (18.4%) 389 (14.5%)
Diabetes, uncomplicated 10,162 5,087 21 8 22,027 0.964 0.709 7,730 5,796 2,449 10,842 11,560 4,747 8,780 4,780 2,950 (13.4%) 9,790 (44.4%)
Diabetes, complicated 848 496 22 11 1,501 0.223 0.327 697 213 262 564 212 115 726 456 241 (16.1%) 278 (18.5%)
Hemiplegia or paraplegia 1,124 570 21 14 2,272 0.859 0.666 919 376 312 1,013 420 194 1,392 740 179 (7.9%) 743 (32.7%)
Renal disease 3,962 2,176 16 10 6,898 0.943 0.743 3,399 784 1,222 2,500 107 62 6,168 3,558 -159 (-2.3%) 2,219 (32.2%)
Malignancy 4,216 2,435 19 9 7,589 0.85 0.702 3,199 1,217 840 2,931 155 89 5,469 3,032 167 (2.2%) 2,061 (27.2%)
Moderate or severe liver disease 359 244 20 7 607 0.227 0.334 298 75 114 211 39 23 330 196 102 (16.8%) 113 (18.6%)
Metastatic solid tumour 1,650 835 17 8 3,034 0.953 0.704 1,246 398 288 1,185 26 17 2,687 1,461 -215 (-7.1%) 1,036 (34.1%)
Congestive heart failure 4,922 2,385 14 10 8,716 0.913 0.724 4,242 962 1,364 3,185 304 163 7,031 4,053 189 (2.2%) 2,510 (28.8%)
AIDS/HIV 102 67 13 6 442 0.676 0.543 69 257 20 329 219 49 89 23 46 (10.4%) 225 (50.9%)
a The Charlson Comorbidity Index (CCI) diagnoses groups. b Total number of patients with prior spells. c The Inter-Quartile Range (IQR) of patients’ age.
d The IQR of patients’ length-of-stay. e Sensitivity, 50% cut-off point. f F1-score, 50% cut-off point. g True Positive (TP), 50% cut-off point. h True Negative (TN), 50%
cut-off point. i Total number of patients scored between 1 to 3 by the NHS-CCI. j Subtraction of TCARER’s True Positive (50% cut-off point) from the NHS-CCI of 4+.
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Table A.5
The profile of T-CARER WDNN model and NHS-CCI (365-day), using ECI diagnoses categories (Sample-2, 2004–2009).
Elixhauser comorbidity in-
dex
Population profile T-CARER profile NHS-CCI profile Comparisons





































Congestive heart failure 1,650 835 17 8 3,034 0.486 0.533 802 825 229 1,224 26 17 2,687 1,461 -659 (-21.7%) 1,075 (35.4%)
AIDS/HIV 102 67 13 6 442 0.422 0.446 43 292 15 331 219 49 89 23 20 (4.5%) 227 (51.4%)
Depression 3,029 1,114 38 8 7,196 0.487 0.522 1,474 3,018 498 3,940 327 142 1,462 733 741 (10.3%) 687 (9.5%)
Cardiac arrhythmias 11,194 5,377 14 8 23,006 0.573 0.581 6,409 7,345 2,416 10,650 1,550 764 10,033 5,520 889 (3.9%) 4,137 (18.0%)
Valvular disease 2,019 942 16 10 3,957 0.555 0.577 1,121 1,194 423 1,750 228 109 1,868 1,067 54 (1.4%) 732 (18.5%)
Pulmonary circulation disorder 806 377 22 10 1,745 0.476 0.525 384 665 128 885 101 41 729 397 -13 (-0.7%) 338 (19.4%)
Peripheral vascular disorders 1,980 1,236 14 11 3,780 0.579 0.597 1,146 1,085 465 1,621 108 63 3,074 1,650 -504 (-13.3%) 1,290 (34.1%)
Hypertension, uncomplicated 19,370 8,554 18 8 46,496 0.482 0.512 9,344 19,325 3,029 25,608 5,932 2,400 16,643 8,131 1,213 (2.6%) 10,526 (22.6%)
Hypertension, complicated 1,702 911 15 11 3,002 0.612 0.624 1,041 709 431 1,128 52 30 2,701 1,545 -504 (-16.8%) 1,006 (33.5%)
Paralysis 1,124 570 21 14 2,272 0.558 0.571 627 702 262 1,040 420 194 1,392 740 -113 (-5.0%) 770 (33.9%)
Other neurological disorders 5,672 2,863 35 8 11,863 0.567 0.594 3,214 4,257 1,161 5,762 604 310 3,513 1,944 1,270 (10.7%) 1,434 (12.1%)
Chronic pulmonary disease 13,510 5,865 30 6 30,516 0.589 0.598 7,958 11,845 3,453 15,782 491 269 24,090 10,669 -2,711 (-8.9%) 12,419 (40.7%)
Diabetes, uncomplicated 10,110 5,054 21 8 21,907 0.571 0.578 5,773 7,712 2,260 10,793 11,516 4,729 8,737 4,757 1,016 (4.6%) 9,763 (44.6%)
Diabetes, complicated 887 516 21 11 1,603 0.59 0.619 523 435 217 643 248 129 761 472 51 (3.2%) 335 (20.9%)
Hypothyroidism 3,394 685 19 9 7,859 0.534 0.551 1,812 3,089 723 4,150 695 312 2,940 1,539 273 (3.5%) 1,469 (18.7%)
Renal failure 3,956 2,173 16 10 6,883 0.634 0.643 2,510 1,580 1,081 2,516 106 61 6,161 3,556 -1,046 (-15.2%) 2,239 (32.5%)
Liver disease 1,527 939 22 7 2,955 0.599 0.623 914 937 353 1,319 189 96 1,157 668 246 (8.3%) 473 (16.0%)
Peptic ulcer disease 464 233 23 11 1,158 0.502 0.531 233 514 75 654 43 16 711 306 -73 (-6.3%) 392 (33.9%)
Psychoses 1,121 641 29 31 2,571 0.498 0.518 558 974 149 1,372 103 45 332 175 383 (14.9%) 137 (5.3%)
Lymphoma 462 246 18 10 743 0.543 0.598 251 155 91 238 15 9 478 289 -38 (-5.1%) 152 (20.5%)
Metastatic cancer 1,650 835 17 8 3,034 0.486 0.533 802 825 229 1,224 26 17 2,687 1,461 -659 (-21.7%) 1,075 (35.4%)
Solid tumour 3,510 2,062 18 9 6,425 0.512 0.557 1,796 1,775 587 2,618 131 74 4,750 2,621 -825 (-12.8%) 1,889 (29.4%)
Rheumatoid arthritis 1,603 458 19 8 3,833 0.558 0.563 895 1,548 315 2,068 64 28 3,176 1,369 -474 (-12.4%) 1,681 (43.9%)
Coagulopathy 416 175 40 8 1,003 0.55 0.586 229 451 90 547 42 19 265 140 89 (8.9%) 108 (10.8%)
Obesity 853 343 29 7 2,009 0.522 0.561 445 868 184 1,112 307 136 704 357 88 (4.4%) 474 (23.6%)
Weight loss 709 369 23 12 1,483 0.434 0.494 308 543 88 728 70 29 490 267 41 (2.8%) 218 (14.7%)
Fluid & electrolyte disorders 2,850 1,161 19 14 5,901 0.55 0.567 1,567 1,937 538 2,770 375 182 2,599 1,372 195 (3.3%) 1,139 (19.3%)
Blood loss anemia 69 30 28 8 204 0.435 0.451 30 101 12 128 8 2 51 26 4 (2.0%) 24 (11.8%)
Deficiency anemia 5,006 2,975 33 7 12,003 0.552 0.576 2,763 5,172 995 6,656 525 254 2,548 1,361 1,402 (11.7%) 1,117 (9.3%)
Alcohol abuse 2,132 1,313 23 5 5,421 0.514 0.554 1,095 2,560 366 3,179 175 81 997 547 548 (10.1%) 434 (8.0%)
Drug abuse 941 614 13 5 2,548 0.454 0.5 427 1,268 131 1,559 33 15 261 109 318 (12.5%) 122 (4.8%)




Population profile T-CARER profile NHS-CCI profile Comparisons





































a The Elixhauser Comorbidity Index (ECI) diagnoses groups. b Total number of patients with prior spells. c The Inter-Quartile Range (IQR) of patients’ age.
d The IQR of patients’ length-of-stay. e Sensitivity, 50% cut-off point. f F1-score, 50% cut-off point. g True Positive (TP), 50% cut-off point. h True Negative (TN), 50%
cut-off point. i Total number of patients scored between 1 to 3 by the NHS-CCI. j Subtraction of TCARER’s True Positive (50% cut-off point) from the NHS-CCI of 4+.
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Table A.6
The profile of T-CARER WDNN model and NHS-CCI (365-day), using CCI diagnoses categories (Sample-2 2004–2009).
Charlson comorbidity in-
dex
Population profile T-CARER profile NHS-CCI profile Comparisons





































Myocardial infarction 4,079 2,600 21 5 7,806 0.41 0.491 1,671 2,670 536 3,504 396 221 4,493 2,373 -702 (-9.0%) 2,072 (26.5%)
Peripheral vascular disease 4,922 2,385 14 10 8,716 0.611 0.623 3,009 2,065 1,271 3,231 304 163 7,031 4,053 -1,044 (-
12.0%)
2,556 (29.3%)
Cerebrovascular disease 1,980 1,236 14 11 3,780 0.579 0.597 1,146 1,085 465 1,621 108 63 3,074 1,650 -504 (-13.3%) 1,290 (34.1%)
Dementia 4,651 2,206 16 14 9,911 0.488 0.525 2,269 3,529 768 4,896 598 277 5,457 2,795 -526 (-5.3%) 2,619 (26.4%)
Chronic pulmonary disease 4,020 1,407 9 15 7,766 0.621 0.591 2,496 1,819 795 3,235 100 55 6,380 3,312 -816 (-10.5%) 2,602 (33.5%)
Rheumatic disease 13,510 5,865 30 6 30,516 0.589 0.598 7,958 11,845 3,453 15,782 491 269 24,090 10,669 -2,711 (-8.9%) 12,419 (40.7%)
Peptic ulcer disease 1,462 394 16 9 3,438 0.573 0.572 837 1,349 296 1,823 34 15 3,110 1,342 -505 (-14.7%) 1,634 (47.5%)
Mild liver disease 695 370 23 10 1,817 0.453 0.498 315 867 98 1,069 76 24 935 405 -90 (-5.0%) 529 (29.1%)
Diabetes, uncomplicated 1,393 853 22 7 2,691 0.614 0.633 855 843 337 1,195 167 83 1,054 613 242 (9.0%) 422 (15.7%)
Diabetes, complicated 10,162 5,087 21 8 22,027 0.571 0.578 5,807 7,756 2,273 10,856 11,560 4,747 8,780 4,780 1,027 (4.7%) 9,804 (44.5%)
Hemiplegia or paraplegia 848 496 22 11 1,501 0.586 0.62 497 394 208 585 212 115 726 456 41 (2.7%) 299 (19.9%)
Renal disease 1,124 570 21 14 2,272 0.558 0.571 627 702 262 1,040 420 194 1,392 740 -113 (-5.0%) 770 (33.9%)
Malignancy 3,962 2,176 16 10 6,898 0.634 0.642 2,512 1,586 1,081 2,524 107 62 6,168 3,558 -1,046 (-
15.2%)
2,243 (32.5%)
Moderate or severe liver disease 4,216 2,435 19 9 7,589 0.511 0.561 2,156 2,062 722 3,020 155 89 5,469 3,032 -876 (-11.5%) 2,150 (28.3%)
Metastatic solid tumour 359 244 20 7 607 0.577 0.617 207 143 91 224 39 23 330 196 11 (1.8%) 126 (20.8%)
Congestive heart failure 1,650 835 17 8 3,034 0.486 0.533 802 825 229 1,224 26 17 2,687 1,461 -659 (-21.7%) 1,075 (35.4%)
AIDS/HIV 102 67 13 6 442 0.422 0.446 43 292 15 331 219 49 89 23 20 (4.5%) 227 (51.4%)
a The Charlson Comorbidity Index (CCI) diagnoses groups. b Total number of patients with prior spells. c The Inter-Quartile Range (IQR) of patients’ age.
d The IQR of patients’ length-of-stay. e Sensitivity, 50% cut-off point. f F1-score, 50% cut-off point. g True Positive (TP), 50% cut-off point. h True Negative (TN), 50%
cut-off point. i Total number of patients scored between 1 to 3 by the NHS-CCI. j Subtraction of TCARER’s True Positive (50% cut-off point) from the NHS-CCI of 4+.
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Table A.7
The weights of features using the Random Forest method for Sample-2 (2004-2009).
# Name Weight Temporal Definition
1 mainspef 0t30d prevalence 2 cnt 9.33E-02 0-30 Main Speciality: Maternity
2 diagCCS 0t30d prevalence 10 cnt 6.60E-02 0-30 CCS group: Other complications of pregnancy
3 epidur 0t30d avg 5.93E-02 0-30 Average episode duration
4 posopdur 0t30d avg 5.79E-02 0-30 Average Post-operation duration
5 gender 1 5.09E-02 Trigger Gender: Male
6 diagCCS 0t30d prevalence 3 cnt 4.77E-02 0-30 CCS group: Normal pregnancy and delivery
7 diagCCS 0t30d prevalence 13 cnt 4.23E-02 0-30 CCS group: OB-related trauma to perineum & vulva
8 diagCCS 0t30d others cnt 3.50E-02 0-30 CCS group: others
9 ethnos 0 3.11E-02 Trigger ethnicity: Not known
10 mainspef 0t30d prevalence 5 cnt 2.80E-02 0-30 Main Speciality: Gynaecology
11 operOPCSL1 0t30d prevalence 1 cnt 2.05E-02 0-30 Operation group: Female Genital Tract
12 posopdur 365t730d others cnt 2.04E-02 365-730 Post-operation duration
13 diagCCS 0t30d prevalence 22 cnt 1.93E-02 0-30 CCS group: Fetal distress & abnormal forces of labor
14 mainspef 0t30d prevalence 6 cnt 1.90E-02 0-30 Main Speciality: Plastic
15 preopdur 180t365d others cnt 1.80E-02 180-365 Pre-operation duration
16 epidur 365t730d avg 1.80E-02 365-730 Average episode duration
17 gapDays 365t730d avg 1.74E-02 365-730 Average Gap-Days
18 preopdur 365t730d others cnt 1.71E-02 365-730 Pre-operation duration
19 mainspef 0t30d prevalence 1 cnt 1.71E-02 0-30 Main Speciality: General
20 gapDays 365t730d others cnt 1.54E-02 365-730 Gap-Days
21 preopdur 0t30d avg 1.47E-02 0-30 Average Pre-operation duration
22 admimeth 180t365d prevalence 1 cnt 1.33E-02 180-365 Admission method: Unknown
23 epidur 365t730d others cnt 1.30E-02 365-730 Episode duration
24 epidur 0t30d others cnt 1.10E-02 0-30 Episode duration
25 mainspef 0t30d prevalence 9 cnt 1.06E-02 0-30 Main Speciality: Paediatrics
26 mainspef 0t30d prevalence 4 cnt 1.06E-02 0-30 Main Speciality: A&E
27 diagCCS 365t730d others cnt 9.36E-03 365-730 CCS group: others
28 admimeth 365t730d prevalence 1 cnt 7.48E-03 365-730 Admission method: Unknown
29 mainspef 0t30d prevalence 3 cnt 7.40E-03 0-30 Main Speciality: General Surgery
30 diagCCS 90t180d others cnt 7.32E-03 90-180 CCS group: others
31 diagCCS 180t365d others cnt 7.27E-03 180-365 CCS group: others
32 diagCCS 0t30d prevalence 7 cnt 7.18E-03 0-30 CCS group: Abdominal pain
33 mainspef 180t365d others cnt 6.95E-03 180-365 Main Speciality: Others
34 diagCCS 0t30d prevalence 24 cnt 6.77E-03 0-30 CCS group: Other birth complications; mother’s puer-
perium
35 epidur 90t180d others cnt 6.22E-03 90-180 Episode duration
36 ethnos 1 5.97E-03 Trigger ethnicity: White
37 epidur 180t365d avg 5.79E-03 180-365 Average episode duration
38 mainspef 0t30d prevalence 7 cnt 5.76E-03 0-30 Main Speciality: Geriatric
39 posopdur 180t365d others cnt 5.35E-03 180-365 Post-operation duration
40 diagCCS 0t30d prevalence 16 cnt 5.25E-03 0-30 CCS group: Chronic obstructive pulmonary &
bronchiectasis
41 admimeth 90t180d prevalence 1 cnt 5.13E-03 90-180 Admission method: Unknown
42 epidur 180t365d others cnt 4.97E-03 180-365 Episode duration
43 diagCCS 0t30d prevalence 11 cnt 4.85E-03 0-30 CCS group: Other upper respiratory disease
44 operOPCSL1 0t30d others cnt 4.50E-03 0-30 Operation group: Others
45 gapDays 180t365d avg 4.34E-03 180-365 Average Gap-Days




# Name Weight Temporal Definition
47 posopdur 0t30d others cnt 3.74E-03 0-30 Post-operation duration
48 diagCCS 0t30d prevalence 21 cnt 3.68E-03 0-30 CCS group: Delirium dementia & amnestic & other
cognitives
49 mainspef 180t365d prevalence 1 cnt 3.49E-03 180-365 Main Speciality: General
50 diagCCS 0t30d prevalence 1 cnt 3.37E-03 0-30 CCS group: Others
51 diagCCS 0t30d prevalence 5 cnt 3.14E-03 0-30 CCS group: Coronary atherosclerosis & other heart
disease
52 mainspef 90t180d others cnt 3.09E-03 90-180 Main Speciality: Others
53 mainspef 0t30d others cnt 2.88E-03 0-30 Main Speciality: Others
54 diagCCS 30t90d others cnt 2.86E-03 30-90 CCS group: others
55 gapDays 90t180d avg 2.73E-03 90-180 Average Gap-Days
56 gapDays 90t180d others cnt 2.69E-03 90-180 Gap-Days
57 admimeth 90t180d others cnt 2.47E-03 90-180 Admission method: Others
58 admimeth 30t90d prevalence 1 cnt 2.46E-03 30-90 Admission method: Unknown
59 gapDays 30t90d avg 2.23E-03 30-90 Average Gap-Days
60 posopdur 30t90d others cnt 2.09E-03 30-90 Post-operation duration
61 diagCCS 0t30d prevalence 29 cnt 2.03E-03 0-30 CCS group: Other injuries & conditions due to exter-
nal causes
62 gapDays 180t365d others cnt 1.99E-03 180-365 Gap-Days
63 preopdur 0t30d others cnt 1.88E-03 0-30 Pre-operation duration
64 diagCCS 0t30d prevalence 6 cnt 1.83E-03 0-30 CCS group: Cardiac dysrhythmias
65 admimeth 180t365d others cnt 1.82E-03 180-365 Admission method: Others
66 posopdur 90t180d others cnt 1.75E-03 90-180 Post-operation duration
67 epidur 30t90d others cnt 1.67E-03 30-90 Episode duration
68 diagCCS 365t730d prevalence 4 cnt 1.62E-03 365-730 CCS group: Normal pregnancy and/or delivery
69 admimeth 365t730d others cnt 1.60E-03 365-730 Admission method: Others
70 mainspef 30t90d others cnt 1.58E-03 30-90 Main Speciality: Others
71 diagCCS 0t30d prevalence 4 cnt 1.54E-03 0-30 CCS group: Residual codes; unclassified
72 diagCCS 0t30d prevalence 9 cnt 1.45E-03 0-30 CCS group: Diabetes mellitus without complication
73 epidur 90t180d avg 1.44E-03 90-180 Average episode duration
74 mainspef 0t30d prevalence 8 cnt 1.40E-03 0-30 Main Speciality: Cardiothoracic
75 admimeth 365t730d prevalence 2 cnt 1.31E-03 365-730 Admission method: Elective
76 diagCCS 0t30d prevalence 17 cnt 1.29E-03 0-30 CCS group: Urinary tract infections
77 diagCCS 365t730d prevalence 12 cnt 1.19E-03 365-730 CCS group: Other complications of pregnancy
78 diagCCS 365t730d prevalence 1 cnt 1.15E-03 365-730 CCS group: Others
79 diagCCS 0t30d prevalence 12 cnt 9.98E-04 0-30 CCS group: Asthma
80 mainspef 180t365d prevalence 3 cnt 9.82E-04 180-365 Main Speciality: Gynaecology
81 preopdur 30t90d others cnt 9.59E-04 30-90 Pre-operation duration
82 posopdur 365t730d avg 9.39E-04 365-730 Average Post-operation duration
83 mainspef 90t180d prevalence 1 cnt 9.33E-04 90-180 Main Speciality: General
84 diagCCS 0t30d prevalence 8 cnt 8.77E-04 0-30 CCS group: External cause codes: Fall
85 mainspef 0t30d prevalence 10 cnt 8.66E-04 0-30 Main Speciality: Gastroenterology
86 diagCCS 0t30d prevalence 20 cnt 8.31E-04 0-30 CCS group: Other connective tissue disease
87 diagCCS 180t365d prevalence 1 cnt 8.23E-04 180-365 CCS group: Others
88 imd04rk 2 8.15E-04 Trigger imd04rk: 3248 to 6496
89 admimeth 180t365d prevalence 2 cnt 7.73E-04 180-365 Admission method: Elective
90 diagCCS 0t30d prevalence 14 cnt 7.62E-04 0-30 CCS group: Other lower respiratory disease
91 diagCCS 0t30d prevalence 28 cnt 7.05E-04 0-30 CCS group: Deficiency & other anemia




# Name Weight Temporal Definition
93 imd04rk 3 6.76E-04 Trigger imd04rk: 6496 to 9745
94 diagCCS 0t30d prevalence 19 cnt 6.69E-04 0-30 CCS group: Phlebitis; thrombophlebitis & throm-
boembolism
95 imd04rk 1 6.60E-04 Trigger imd04rk: 0 to 3248
96 epidur 30t90d avg 6.27E-04 30-90 Average episode duration
97 ageTrigger 25 6.14E-04 Trigger Age: 25-30
98 diagCCS 0t30d prevalence 23 cnt 6.11E-04 0-30 CCS group: Allergic reactions
99 operOPCSL1 0t30d prevalence 3 cnt 5.94E-04 0-30 Operation group: Lower Digestive Tract
100 ageTrigger 85 5.85E-04 Trigger Age: 85+
101 admimeth 30t90d others cnt 5.73E-04 30-90 Admission method: Others
102 diagCCS 365t730d prevalence 7 cnt 5.61E-04 365-730 CCS group: Cardiac dysrhythmias
103 diagCCS 0t30d prevalence 25 cnt 5.57E-04 0-30 CCS group: Complication of device; implant or graft
104 diagCCS 0t30d prevalence 18 cnt 5.49E-04 0-30 CCS group: Other gastrointestinal disorders
105 diagCCS 90t180d prevalence 9 cnt 5.45E-04 90-180 CCS group: Other complications of pregnancy
106 preopdur 90t180d others cnt 5.44E-04 90-180 Pre-operation duration
107 posopdur 180t365d avg 5.17E-04 180-365 Average Post-operation duration
108 diagCCS 365t730d prevalence 13 cnt 4.91E-04 365-730 CCS group: Chronic obstructive pulmonary &
bronchiectasis
109 imd04rk 6 4.84E-04 Trigger imd04rk: 16241 to 19489
110 gapDays 30t90d others cnt 4.40E-04 30-90 Gap-Days
111 imd04rk 5 4.30E-04 Trigger imd04rk: 12993 to 16241
112 ageTrigger 35 4.22E-04 Trigger Age: 35-40
113 preopdur 90t180d avg 4.11E-04 90-180 Average Pre-operation duration
114 operOPCSL1 0t30d prevalence 8 cnt 4.04E-04 0-30 Operation group: Upper Female Genital Tract
115 ageTrigger 15 4.03E-04 Trigger Age: 15-20
116 imd04rk 4 4.02E-04 Trigger imd04rk: 9745 to 12993
117 imd04rk 8 3.96E-04 Trigger imd04rk: 22737 to 25986
118 diagCCS 180t365d prevalence 2 cnt 3.93E-04 180-365 CCS group: Essential hypertension
119 imd04rk 7 3.88E-04 Trigger imd04rk: 19489 to 22737
120 diagCCS 0t30d prevalence 15 cnt 3.85E-04 0-30 CCS group: Disorders of lipid metabolism
121 mainspef 180t365d prevalence 6 cnt 3.83E-04 180-365 Main Speciality: Plastic
122 ageTrigger 80 3.75E-04 Trigger Age: 80-85
123 diagCCS 365t730d prevalence 5 cnt 3.68E-04 365-730 CCS group: Coronary atherosclerosis & other heart
disease
124 ageTrigger 60 3.55E-04 Trigger Age: 60-65
125 diagCCS 180t365d prevalence 9 cnt 3.44E-04 180-365 CCS group: Chronic obstructive pulmonary &
bronchiectasis
126 imd04rk 9 3.42E-04 Trigger imd04rk: 25986 to 29234
127 preopdur 365t730d avg 3.27E-04 365-730 Average Pre-operation duration
128 admimeth 30t90d prevalence 2 cnt 3.23E-04 30-90 Admission method: Elective
129 diagCCS 365t730d prevalence 3 cnt 3.15E-04 365-730 CCS group: Essential hypertension
130 ageTrigger 30 3.12E-04 Trigger Age: 30-35
131 operOPCSL1 0t30d prevalence 4 cnt 3.11E-04 0-30 Operation group: Diagnostics & Tests
132 diagCCS 0t30d prevalence 30 cnt 3.05E-04 0-30 CCS group: Thyroid disorders
133 ethnos 3 3.02E-04 Trigger ethnicity: Pakistani
134 operOPCSL1 0t30d prevalence 2 cnt 2.99E-04 0-30 Operation group: Miscellaneous Operations
135 diagCCS 365t730d prevalence 2 cnt 2.96E-04 365-730 CCS group: Residual codes; unclassified
136 mainspef 180t365d prevalence 4 cnt 2.87E-04 180-365 Main Speciality: Geriatric




# Name Weight Temporal Definition
138 admimeth 90t180d prevalence 2 cnt 2.73E-04 90-180 Admission method: Elective
139 diagCCS 365t730d prevalence 28 cnt 2.71E-04 365-730 CCS group: Cataract
140 ageTrigger 45 2.57E-04 Trigger Age: 45-50
141 ethnos 9 2.39E-04 Trigger ethnicity: Any other
142 diagCCS 365t730d prevalence 6 cnt 2.36E-04 365-730 CCS group: Diabetes mellitus without complication
143 operOPCSL1 365t730d others cnt 2.36E-04 365-730 Operation group: Others
144 mainspef 90t180d prevalence 5 cnt 1.95E-04 90-180 Main Speciality: Maternity
145 diagCCS 180t365d prevalence 20 cnt 1.95E-04 180-365 CCS group: Other complications of pregnancy
146 diagCCS 365t730d prevalence 29 cnt 1.94E-04 365-730 CCS group: Other birth complications; mother’s puer-
perium
147 mainspef 90t180d prevalence 3 cnt 1.78E-04 90-180 Main Speciality: Gynaecology
148 diagCCS 365t730d prevalence 9 cnt 1.74E-04 365-730 CCS group: Abdominal pain
149 mainspef 30t90d prevalence 2 cnt 1.69E-04 30-90 Main Speciality: Maternity
150 mainspef 30t90d prevalence 1 cnt 1.68E-04 30-90 Main Speciality: General
151 ageTrigger 50 1.68E-04 Trigger Age: 50-55
152 operOPCSL1 365t730d prevalence 4 cnt 1.67E-04 365-730 Operation group: Upper Female Genital Tract
153 ageTrigger 20 1.65E-04 Trigger Age: 20-25
154 mainspef 180t365d prevalence 5 cnt 1.64E-04 180-365 Main Speciality: A&E
155 gapDays 0t30d avg 1.64E-04 0-30 Average Gap-Days
156 posopdur 90t180d avg 1.64E-04 90-180 Average Post-operation duration
157 diagCCS 90t180d prevalence 2 cnt 1.56E-04 90-180 CCS group: Essential hypertension
158 diagCCS 365t730d prevalence 20 cnt 1.54E-04 365-730 CCS group: Administrative/social admission
159 operOPCSL1 0t30d prevalence 16 cnt 1.51E-04 0-30 Operation group: Lower Female Genital Tract
160 diagCCS 30t90d prevalence 5 cnt 1.50E-04 30-90 CCS group: Other complications of pregnancy
161 diagCCS 90t180d prevalence 1 cnt 1.45E-04 90-180 CCS group: Others
162 diagCCS 180t365d prevalence 28 cnt 1.38E-04 180-365 CCS group: Congestive heart failure; nonhypertensive
163 preopdur 180t365d avg 1.37E-04 180-365 Average Pre-operation duration
164 diagCCS 365t730d prevalence 14 cnt 1.34E-04 365-730 CCS group: Other lower respiratory disease
165 operOPCSL1 180t365d others cnt 1.34E-04 180-365 Operation group: Others
166 mainspef 90t180d prevalence 6 cnt 1.28E-04 90-180 Main Speciality: A&E
167 diagCCS 365t730d prevalence 30 cnt 1.24E-04 365-730 CCS group: Fetal distress & abnormal forces of labor
168 diagCCS 365t730d prevalence 16 cnt 1.20E-04 365-730 CCS group: Complication of device; implant or graft
169 diagCCS 90t180d prevalence 17 cnt 1.19E-04 90-180 CCS group: Normal pregnancy and/or delivery
170 ethnos 7 1.18E-04 Trigger ethnicity: Black - Other
171 diagCCS 180t365d prevalence 8 cnt 1.14E-04 180-365 CCS group: Abdominal pain
172 diagCCS 365t730d prevalence 11 cnt 1.13E-04 365-730 CCS group: Other gastrointestinal disorders
173 operOPCSL1 0t30d prevalence 5 cnt 1.08E-04 0-30 Operation group: Urinary
174 diagCCS 30t90d prevalence 12 cnt 1.08E-04 30-90 CCS group: Normal pregnancy and/or delivery
175 ageTrigger 55 1.07E-04 Trigger Age: 55-60
176 mainspef 180t365d prevalence 9 cnt 1.00E-04 180-365 Main Speciality: Maternity
177 diagCCS 90t180d prevalence 7 cnt 9.95E-05 90-180 CCS group: Chronic obstructive pulmonary &
bronchiectasis
178 ageTrigger 75 9.56E-05 Trigger Age: 75-80
179 diagCCS 180t365d prevalence 4 cnt 9.53E-05 180-365 CCS group: Coronary atherosclerosis & other heart
disease
180 diagCCS 365t730d prevalence 10 cnt 9.40E-05 365-730 CCS group: Other upper respiratory disease
181 diagCCS 365t730d prevalence 8 cnt 9.34E-05 365-730 CCS group: Asthma
182 ageTrigger 40 9.26E-05 Trigger Age: 40-45




# Name Weight Temporal Definition
184 diagCCS 90t180d prevalence 15 cnt 8.65E-05 90-180 CCS group: Other upper respiratory disease
185 diagCCS 365t730d prevalence 22 cnt 8.55E-05 365-730 CCS group: OB-related trauma to perineum & vulva
186 diagCCS 365t730d prevalence 18 cnt 8.52E-05 365-730 CCS group: External cause codes: Fall
187 diagCCS 180t365d prevalence 19 cnt 8.33E-05 180-365 CCS group: Normal pregnancy and/or delivery
188 ethnos 6 8.31E-05 Trigger ethnicity: Black - African
189 diagCCS 180t365d prevalence 5 cnt 7.85E-05 180-365 CCS group: Diabetes mellitus without complication
190 diagCCS 365t730d prevalence 26 cnt 7.83E-05 365-730 CCS group: Genitourinary symptoms & ill-defined
conditions
191 diagCCS 365t730d prevalence 15 cnt 7.72E-05 365-730 CCS group: Phlebitis; thrombophlebitis & throm-
boembolism
192 diagCCS 30t90d prevalence 1 cnt 7.68E-05 30-90 CCS group: Others
193 mainspef 180t365d prevalence 2 cnt 7.60E-05 180-365 Main Speciality: General Surgery
194 ethnos 2 7.27E-05 Trigger ethnicity: Indian
195 ethnos 5 6.89E-05 Trigger ethnicity: Black - Caribbean
196 diagCCS 365t730d prevalence 21 cnt 6.70E-05 365-730 CCS group: Disorders of lipid metabolism
197 mainspef 90t180d prevalence 7 cnt 6.49E-05 90-180 Main Speciality: Plastic
198 operOPCSL1 180t365d prevalence 1 cnt 6.42E-05 180-365 Operation group: Miscellaneous Operations
199 operOPCSL1 365t730d prevalence 3 cnt 6.26E-05 365-730 Operation group: Female Genital Tract
200 diagCCS 180t365d prevalence 7 cnt 6.23E-05 180-365 CCS group: Asthma
201 diagCCS 180t365d prevalence 3 cnt 6.11E-05 180-365 CCS group: Residual codes; unclassified
202 diagCCS 365t730d prevalence 24 cnt 6.08E-05 365-730 CCS group: Other screening (excl. mental & infec-
tious)
203 diagCCS 90t180d prevalence 24 cnt 6.04E-05 90-180 CCS group: Alcohol-related disorders
204 diagCCS 180t365d prevalence 6 cnt 6.03E-05 180-365 CCS group: Cardiac dysrhythmias
205 ageTrigger 70 5.71E-05 Trigger Age: 70-75
206 diagCCS 90t180d prevalence 8 cnt 5.54E-05 90-180 CCS group: Abdominal pain
207 diagCCS 365t730d prevalence 23 cnt 5.13E-05 365-730 CCS group: Allergic reactions
208 diagCCS 365t730d prevalence 17 cnt 5.09E-05 365-730 CCS group: Other connective tissue disease
209 diagCCS 180t365d prevalence 27 cnt 5.05E-05 180-365 CCS group: Delirium dementia & amnestic & other
cognitives
210 operOPCSL1 0t30d prevalence 7 cnt 4.98E-05 0-30 Operation group: Soft Tissue
211 diagCCS 180t365d prevalence 16 cnt 4.98E-05 180-365 CCS group: Disorders of lipid metabolism
212 ageTrigger 65 4.85E-05 Trigger Age: 65-70
213 ethnos 4 4.84E-05 Trigger ethnicity: Bangladeshi
214 diagCCS 365t730d prevalence 19 cnt 4.78E-05 365-730 CCS group: Urinary tract infections
215 mainspef 30t90d prevalence 8 cnt 4.69E-05 30-90 Main Speciality: Plastic
216 operOPCSL1 365t730d prevalence 2 cnt 4.59E-05 365-730 Operation group: Urinary
217 diagCCS 180t365d prevalence 17 cnt 4.57E-05 180-365 CCS group: External cause codes: Fall
218 diagCCS 365t730d prevalence 25 cnt 4.10E-05 365-730 CCS group: Other nervous system disorders
219 diagCCS 180t365d prevalence 25 cnt 4.03E-05 180-365 CCS group: Administrative/social admission
220 diagCCS 365t730d prevalence 27 cnt 3.87E-05 365-730 CCS group: Deficiency & other anemia
221 diagCCS 180t365d prevalence 26 cnt 3.70E-05 180-365 CCS group: Genitourinary symptoms & ill-defined
conditions
222 mainspef 90t180d prevalence 2 cnt 3.64E-05 90-180 Main Speciality: General Surgery
223 diagCCS 180t365d prevalence 12 cnt 3.63E-05 180-365 CCS group: Phlebitis; thrombophlebitis & throm-
boembolism
224 diagCCS 90t180d prevalence 5 cnt 3.61E-05 90-180 CCS group: Diabetes mellitus without complication
225 gapDays 0t30d others cnt 3.42E-05 0-30 Gap-Days
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227 diagCCS 180t365d prevalence 30 cnt 3.30E-05 180-365 CCS group: Mood disorders
228 diagCCS 180t365d prevalence 24 cnt 3.23E-05 180-365 CCS group: Alcohol-related disorders
229 operOPCSL1 365t730d prevalence 1 cnt 2.98E-05 365-730 Operation group: Miscellaneous Operations
230 preopdur 30t90d avg 2.90E-05 30-90 Average Pre-operation duration
231 diagCCS 30t90d prevalence 3 cnt 2.76E-05 30-90 CCS group: Residual codes; unclassified
232 diagCCS 90t180d prevalence 20 cnt 2.71E-05 90-180 CCS group: Congestive heart failure; nonhypertensive
233 diagCCS 180t365d prevalence 11 cnt 2.68E-05 180-365 CCS group: Other upper respiratory disease
234 operOPCSL1 0t30d prevalence 12 cnt 2.66E-05 0-30 Operation group: Mental Health
235 diagCCS 90t180d prevalence 25 cnt 2.64E-05 90-180 CCS group: Other screening (excl. mental & infec-
tious)
236 diagCCS 30t90d prevalence 8 cnt 2.53E-05 30-90 CCS group: Abdominal pain
237 diagCCS 180t365d prevalence 10 cnt 2.51E-05 180-365 CCS group: Other gastrointestinal disorders
238 operOPCSL1 365t730d prevalence 6 cnt 2.25E-05 365-730 Operation group: Heart
239 diagCCS 180t365d prevalence 22 cnt 2.15E-05 180-365 CCS group: Deficiency & other anemia
240 diagCCS 180t365d prevalence 14 cnt 2.14E-05 180-365 CCS group: Other lower respiratory disease
241 admimeth 0t30d prevalence 2 cnt 2.11E-05 0-30 Admission method: Elective
242 diagCCS 180t365d prevalence 29 cnt 2.11E-05 180-365 CCS group: Epilepsy; convulsions
243 mainspef 180t365d prevalence 8 cnt 2.09E-05 180-365 Main Speciality: Gastroenterology
244 diagCCS 90t180d prevalence 18 cnt 1.99E-05 90-180 CCS group: Disorders of lipid metabolism
245 operOPCSL1 365t730d prevalence 5 cnt 1.97E-05 365-730 Operation group: Lower Digestive Tract
246 mainspef 180t365d prevalence 10 cnt 1.86E-05 180-365 Main Speciality: Urology
247 operOPCSL1 365t730d prevalence 10 cnt 1.83E-05 365-730 Operation group: Diagnostics & Tests
248 operOPCSL1 365t730d prevalence 7 cnt 1.72E-05 365-730 Operation group: Upper Digestive Tract
249 operOPCSL1 30t90d others cnt 1.60E-05 30-90 Operation group: Others
250 posopdur 30t90d avg 1.38E-05 30-90 Average Post-operation duration
251 mainspef 90t180d prevalence 10 cnt 1.36E-05 90-180 Main Speciality: Urology
252 diagCCS 180t365d prevalence 23 cnt 1.18E-05 180-365 CCS group: Other nervous system disorders
253 operOPCSL1 180t365d prevalence 2 cnt 1.13E-05 180-365 Operation group: Urinary
254 operOPCSL1 90t180d others cnt 1.06E-05 90-180 Operation group: Others
255 mainspef 90t180d prevalence 4 cnt 9.57E-06 90-180 Main Speciality: Geriatric
256 diagCCS 180t365d prevalence 15 cnt 9.27E-06 180-365 CCS group: Urinary tract infections
257 diagCCS 30t90d prevalence 20 cnt 7.40E-06 30-90 CCS group: Other screening (excl. mental & infec-
tious)
258 diagCCS 30t90d prevalence 9 cnt 6.74E-06 30-90 CCS group: Chronic obstructive pulmonary &
bronchiectasis
259 operOPCSL1 90t180d prevalence 1 cnt 6.66E-06 90-180 Operation group: Miscellaneous Operations
260 diagCCS 180t365d prevalence 18 cnt 5.75E-06 180-365 CCS group: Other connective tissue disease
261 diagCCS 90t180d prevalence 4 cnt 5.75E-06 90-180 CCS group: Coronary atherosclerosis & other heart
disease
262 diagCCS 90t180d prevalence 22 cnt 5.58E-06 90-180 CCS group: Other connective tissue disease
263 diagCCS 90t180d prevalence 11 cnt 5.30E-06 90-180 CCS group: Other gastrointestinal disorders
264 operOPCSL1 180t365d prevalence 5 cnt 5.27E-06 180-365 Operation group: Upper Female Genital Tract
265 mainspef 180t365d prevalence 7 cnt 4.97E-06 180-365 Main Speciality: Cardiothoracic
266 mainspef 30t90d prevalence 3 cnt 4.60E-06 30-90 Main Speciality: General Surgery
267 diagCCS 90t180d prevalence 12 cnt 4.38E-06 90-180 CCS group: Other lower respiratory disease
268 mainspef 30t90d prevalence 4 cnt 4.26E-06 30-90 Main Speciality: Gynaecology
269 diagCCS 30t90d prevalence 19 cnt 4.23E-06 30-90 CCS group: Congestive heart failure; nonhypertensive
270 diagCCS 30t90d prevalence 14 cnt 4.16E-06 30-90 CCS group: Complication of device; implant or graft




# Name Weight Temporal Definition
272 diagCCS 90t180d prevalence 19 cnt 3.96E-06 90-180 CCS group: External cause codes: Fall
273 operOPCSL1 180t365d prevalence 3 cnt 3.58E-06 180-365 Operation group: Lower Digestive Tract
274 operOPCSL1 180t365d prevalence 12 cnt 3.58E-06 180-365 Operation group: Mental Health
275 diagCCS 30t90d prevalence 10 cnt 3.48E-06 30-90 CCS group: Other gastrointestinal disorders
276 diagCCS 90t180d prevalence 29 cnt 3.48E-06 90-180 CCS group: Other nervous system disorders
277 diagCCS 90t180d prevalence 14 cnt 3.27E-06 90-180 CCS group: Complication of device; implant or graft
278 diagCCS 30t90d prevalence 7 cnt 2.94E-06 30-90 CCS group: Cardiac dysrhythmias
279 operOPCSL1 365t730d prevalence 8 cnt 2.88E-06 365-730 Operation group: Soft Tissue
280 diagCCS 90t180d prevalence 13 cnt 2.58E-06 90-180 CCS group: Phlebitis; thrombophlebitis & throm-
boembolism
281 operOPCSL1 90t180d prevalence 2 cnt 1.66E-06 90-180 Operation group: Urinary
282 diagCCS 180t365d prevalence 21 cnt 1.65E-06 180-365 CCS group: Allergic reactions
283 operOPCSL1 180t365d prevalence 8 cnt 1.24E-06 180-365 Operation group: Female Genital Tract
284 diagCCS 90t180d prevalence 6 cnt 9.76E-07 90-180 CCS group: Cardiac dysrhythmias
285 diagCCS 90t180d prevalence 30 cnt 9.27E-07 90-180 CCS group: Mood disorders
286 diagCCS 30t90d prevalence 4 cnt 8.25E-07 30-90 CCS group: Coronary atherosclerosis & other heart
disease
287 operOPCSL1 0t30d prevalence 9 cnt 7.08E-07 0-30 Operation group: Upper Digestive Tract
288 diagCCS 30t90d prevalence 6 cnt 1.63E-07 30-90 CCS group: Diabetes mellitus without complication
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Fig. A.3. The TensorBoard Graph Visualisation of the designed WDNN.
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Fig. A.4. The TensorBoard Graph Visualisation of the deep part of the designed WDNN.
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Fig. A.5. The TensorBoard Graph Visualisation of the linear part of the designed WDNN.
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